Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America

Clin Infect Dis. 2000 Apr;30(4):658-61. doi: 10.1086/313747. Epub 2000 Apr 20.


Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity. Patients with relatively localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or at high risk of complications because of immunosuppression or other preexisting factors require a variety of treatment strategies that may include antifungal therapy, surgical debridement, or both. Amphotericin B is often selected for treatment of patients with respiratory failure due to Coccidioides immitis or rapidly progressive coccidioidal infections. With other more chronic manifestations of coccidioidomycosis, treatment with fluconazole, itraconazole, or ketoconazole is common. Duration of therapy often ranges from many months to years, and, for some patients, chronic suppressive therapy is needed to prevent relapses.

Publication types

  • Guideline
  • Practice Guideline

MeSH terms

  • Antifungal Agents / therapeutic use
  • Coccidioidomycosis / complications
  • Coccidioidomycosis / diagnosis
  • Coccidioidomycosis / drug therapy
  • Coccidioidomycosis / therapy*
  • Cost-Benefit Analysis
  • Humans
  • Meningitis / etiology
  • Outcome Assessment, Health Care
  • Respiratory Tract Diseases / drug therapy
  • Respiratory Tract Diseases / etiology


  • Antifungal Agents